Home › Compound Library › Tirzepatide
Metabolic and incretin class
Tirzepatide: What the Trials Showed, and How It Compares
The short answer
Tirzepatide is a once-weekly injection that activates two gut hormone receptors at once, GLP-1 and GIP. It is FDA approved as Mounjaro for type 2 diabetes and as Zepbound for obesity, and in its main obesity trial people on the highest dose lost an average of 20.9% of body weight over 72 weeks. It is a prescription medicine.
Questions people ask about Tirzepatide
- Is tirzepatide the same as Ozempic?
- Tirzepatide vs semaglutide: which works better?
- Is tirzepatide FDA approved?
- Is tirzepatide a peptide?
- Tirzepatide vs retatrutide: what is the difference?
- How much weight do people lose on tirzepatide?
- What are tirzepatide’s side effects?
- Does tirzepatide cause muscle loss?
Tirzepatide at a glance
| Also called | Mounjaro (diabetes), Zepbound (obesity); LY3298176 |
|---|---|
| What it is | Synthetic peptide; dual GIP and GLP-1 receptor agonist |
| Main system | Metabolic: appetite, insulin, blood sugar |
| Evidence level | Multiple Phase 3 trials (SURPASS, SURMOUNT programmes) |
| FDA status (Sept 2026) | Approved, prescription only: type 2 diabetes, obesity, and obstructive sleep apnoea with obesity |
| Developer | Eli Lilly and Company |
What is tirzepatide?
Tirzepatide is a manufactured peptide that imitates two hormones your gut releases after a meal: GLP-1 and GIP. Both are incretins, the signals that tell the pancreas to release insulin when food arrives.
Semaglutide, the compound behind Ozempic and Wegovy, acts on GLP-1 alone. Tirzepatide adds GIP, and that second receptor is what the whole compound turns on.
Metabolic Precision (pp. 100–102) profiles it in the incretin category, the class the book calls the primary metabolic engine of most protocols.
How does tirzepatide work?
Through GLP-1 it does what that class does: prompts insulin release when blood sugar is high, suppresses glucagon, slows how fast the stomach empties, and reduces appetite through receptors in the brain.
Through GIP it adds a second insulin signal and engages fat tissue metabolism directly. The combination appears to produce more weight loss than the GLP-1 signal alone, and the reason it works is still being argued over in the literature.
Metabolic Precision (p. 62) makes the wider point: these compounds correct a signalling problem. Appetite, insulin response and gastric emptying are restored toward normal, which is why they are treated as the foundation layer rather than an add-on.
What do the trials show?
Obesity: SURMOUNT-1. Published in the New England Journal of Medicine in 2022. In adults with obesity and without diabetes, average weight loss at 72 weeks was about 15% on the lowest dose and 20.9% on the highest, against 3.1% on placebo (reference 1).
Diabetes: SURPASS-2. A head-to-head against semaglutide in type 2 diabetes, published in 2021. Tirzepatide lowered HbA1c and body weight more than the semaglutide comparator at the doses tested (reference 2). This is one of the few direct comparisons that exists.
Sleep apnoea. A 2024 trial found tirzepatide reduced the severity of obstructive sleep apnoea in people with obesity, which led to that additional approved use (reference 3).
Both Metabolic Precision (p. 353) and The Longevity Map (p. 197) cite this trial programme.
Side effects and cautions
The common effects are gastrointestinal: nausea, diarrhoea, vomiting and constipation, mostly while the dose is being increased. Most people find they settle.
The serious ones are rarer: pancreatitis, gallbladder problems and, in people with existing kidney disease, dehydration from vomiting. There is a boxed warning about thyroid C-cell tumours, based on rodent studies, and it is not for people with a personal or family history of medullary thyroid carcinoma or MEN2.
Metabolic Precision (pp. 223–225) adds the point relevant to anyone stacking: muscle loss during rapid weight loss is a real concern, which is why the book puts protein intake and resistance training alongside these compounds rather than as an afterthought.
This is a prescription medicine with a prescribing framework. Compounded and grey-market copies sit outside it entirely.
Is tirzepatide FDA approved?
Yes. As Mounjaro for type 2 diabetes, approved in 2022; as Zepbound for chronic weight management in obesity, approved in 2023; and with an additional approval for obstructive sleep apnoea in adults with obesity in 2024.
It is prescription only. The versions sold without one are not the approved product, whatever the label says.
Tirzepatide is not named on the 2026 WADA prohibited list, unlike the growth hormone compounds on this site. Athletes should check with their own governing body.
Tirzepatide vs semaglutide and retatrutide
vs semaglutide. One receptor versus two. In the SURPASS-2 head-to-head in type 2 diabetes, tirzepatide produced greater reductions in HbA1c and weight than the semaglutide comparator (reference 2). Side-effect profiles are broadly similar, both dominated by gut symptoms during dose increases.
vs retatrutide. Retatrutide adds a third receptor, glucagon, to the same two. Its Phase 3 trial reported larger average weight loss, but it is still investigational and not approved, so the comparison is between an available medicine and a trial result. See our retatrutide profile.
vs the growth hormone compounds. Different job and different order. Metabolic Precision (pp. 223–225) is explicit: correct the metabolic signal first with this class, and only then consider growth hormone support, because growth hormone reduces insulin sensitivity and works poorly in an insulin-resistant body.
Risk, benefit, and the conversation this page is for
How to weigh it. Some research peptides have a quiet toxicology record, or an unfinished efficacy record. tirzepatide is a different case: on its mechanism it genuinely moves physiology, in this case appetite, insulin signalling and how fast the stomach empties, and that is the reason to weigh it with due diligence rather than enthusiasm. Monitoring is paramount here, and the markers that matter are gastrointestinal tolerance, hydration, and personal thyroid and pancreatic history.
The regulatory picture is moving, selectively. In July 2026 an FDA advisory committee recommended six peptides, BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax, for the list of bulk substances compounding pharmacies may use. Tirzepatide is already approved, which is the far end of the same spectrum this library covers. Reading those decisions one at a time is more useful than treating every compound outside the approved list as equivalent.
Why the class is taken seriously. An approved medicine with years of trial and real-world data is a different proposition from a research compound, and the comparison is worth making in both directions. The useful question is not whether engaging it does anything. It is whether you have done the due diligence to make an informed decision about engaging it at all: what your baseline looks like, what else you are taking, what you would measure along the way, and what would tell you to stop.
Which is the point of the series. Nothing here is a recommendation to use tirzepatide. People misuse approved medicines and unapproved compounds alike, and that is neither the purpose nor the intent of this page. The point is a better conversation than the internet usually allows: with a clinician who knows your history, your labs and everything else you take, and who can help build a plan that fits you.
Tirzepatide: frequently asked questions
Is tirzepatide the same as Ozempic?
No. Ozempic is semaglutide, which acts on GLP-1 only. Tirzepatide acts on GLP-1 and GIP, and is sold as Mounjaro and Zepbound.
Tirzepatide vs semaglutide: which works better?
In the SURPASS-2 head-to-head in type 2 diabetes, tirzepatide produced greater weight and HbA1c reductions than the semaglutide comparator (reference 2). Which suits a given person is a clinical decision, not a league table.
Is tirzepatide FDA approved?
Yes, as Mounjaro for type 2 diabetes, as Zepbound for obesity, and for obstructive sleep apnoea in adults with obesity. Prescription only.
Is tirzepatide a peptide?
Yes. It is a synthetic peptide of 39 amino acids, engineered to activate two incretin receptors and to last about a week in the body.
Tirzepatide vs retatrutide: what is the difference?
Retatrutide adds a glucagon receptor to tirzepatide’s two, and reported larger weight loss in trials. Tirzepatide is approved and available; retatrutide is still investigational.
How much weight do people lose on tirzepatide?
In SURMOUNT-1, average loss at 72 weeks was about 20.9% of body weight on the highest dose, against 3.1% on placebo (reference 1). Individual results vary widely.
What are tirzepatide’s side effects?
Mostly gut-related: nausea, diarrhoea, vomiting, constipation, usually while the dose increases. Rarer risks include pancreatitis and gallbladder problems, and there is a boxed warning about thyroid C-cell tumours based on rodent studies.
Does tirzepatide cause muscle loss?
Rapid weight loss of any kind costs some lean mass. Metabolic Precision (pp. 223–225) treats protein intake and resistance training as part of the protocol rather than optional extras.
Where Tirzepatide appears in our books
This page is the plain-language overview. The books go further: mechanism detail, evidence tiers, how Tirzepatide fits a full protocol, and the cautions that go with it. Page numbers refer to the print editions.
Related compounds
See how Tirzepatide fits a protocol
The free Protocol Builder maps the pathways a compound works on and shows what complements it for your goal, built from the same database as this library.
Open the Protocol BuilderSee the book seriesReferences
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205–216. View sourceCited in Metabolic Precision (p. 353) and The Longevity Map (p. 197)
- Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503–515. View sourceCited in Targeted Peptide Systems (p. 349), The Cognitive Advantage (p. 407) and Metabolic Precision (p. 353)
- Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024;391(13):1193–1205. View source
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. N Engl J Med. 2023;389(6):514–526. View sourceCited in Metabolic Precision (p. 353)
How this page is maintained. Regulatory status and trial results change. We review this page against current sources and update it as new information becomes available; the date at the top shows the last review.
Educational information only, not medical advice. Tirzepatide is discussed here for education. Nothing on this page is a recommendation to use it or a dosing guide. Talk to a qualified clinician before starting, stopping or combining any compound.